- Vienna '18
- Athens 2019
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
Session Title: Intracorneal inlays for correction of presbyopia
Session Date/Time: Tuesday 08/10/2013 | 08:00-10:30
Paper Time: 09:00
Venue: Main Lecture Hall (Ground Floor)
First Author: : C.Baily IRELAND
Co Author(s): : M. O"Keefe Melles
To clinically evaluate the effect of the ICOLENS corneal inlay in the treatment of presbyopia at one year.
Department of Refractive Surgery, Mater Private Hospital, Dublin, Ireland.
A prospective non-randomised clinical study. The inlay has been inserted in the non-dominant eye of 52 eyes through a femtosecond-created pocket. Inclusion criteria included emmetropia (spherical equivalent:-0.5 to +0.75), unambiguous ocular dominance, pupil diameter between 2.4 to 4.2 mm at photopic illumination, central corneal thickness >500µm and uncorrected near visual acuity (UNVA) of 0.4logMAR (20/50) in the non-dominant eye. The optical principle utilised is that of a bifocal lens with a central zone for distance VA and a peripheral optical zone for near VA. Outcome measurements included uncorrected near and distance visual acuity and complication rate.
The mean UNVA in the surgical eye improved preoperatively from N18/N24 to N8 postoperatively (p = 0.000) with 51 patients (98%) reading N16 or better and 14 patients (27%) reading N5 or better. The mean ± SD logMAR UDVA in the surgical eye increased from 0.04 ± 0.13 preoperatively to 0.23 ± 0.15 postoperatively (p = 0.000). There was a mean ± SD loss of 1.69 ± 2.04 lines of vision (p = 0.000). Binocularly there was a mean ± SD gain of 0.56 ± 1.01 lines of vision postoperatively (p = 0.000) with 24 patients (46%) gaining ? 1 line. There were 11 implants explanted due to minimal improvement in UNVA. There were no significant adverse events reported throughout the study.
Implantation of the ICOLENS corneal inlay was a safe and reversible procedure that provided a significant improvement in UNVA associated with a variable loss of monocular UDVA at six months. One year results to follow.
Please wait while information is loading.